Literature DB >> 21464417

Progression-free survival ratio as end point for phase II trials in advanced solid tumors.

Marc Buyse, Emmanuel Quinaux, Alain Hendlisz, Vassilis Golfinopoulos, Christophe Tournigand, Rosemarie Mick.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21464417     DOI： 10.1200/JCO.2010.34.0380

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

Review 1.  Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors:  Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 2.  Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.

Authors:  Christophe Le Tourneau; Maud Kamal; Olivier Trédan; Jean-Pierre Delord; Mario Campone; Anthony Goncalves; Nicolas Isambert; Thierry Conroy; David Gentien; Anne Vincent-Salomon; Anne-Lise Pouliquen; Nicolas Servant; Marc-Henri Stern; Anne-Gaëlle Le Corroller; Sébastien Armanet; Thomas Rio Frio; Xavier Paoletti
Journal:  Target Oncol       Date:  2012-11-17       Impact factor: 4.493

3.  The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.

Authors:  Victor T G Lin; Eddy S Yang
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

4.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

5.  Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

Authors:  Boris Freidlin; Carmen J Allegra; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2020-08-01       Impact factor: 13.506

6.  Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents.

Authors:  C Le Tourneau; V Servois; V Diéras; L Ollivier; P Tresca; X Paoletti
Journal:  Br J Cancer       Date:  2012-01-26       Impact factor: 7.640

7.  Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.

Authors:  Ron Epelbaum; Einat Shacham-Shmueli; Baruch Klein; Abed Agbarya; Baruch Brenner; Ronen Brenner; Eliahu Gez; Talia Golan; Ayala Hubert; Ofer Purim; Mark Temper; Ella Tepper; Andreas Voss; Kenneth Russell; Addie Dvir; Lior Soussan-Gutman; Salomon M Stemmer; Ravit Geva
Journal:  Biomed Res Int       Date:  2015-05-28       Impact factor: 3.411

8.  Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.

Authors:  Andrea Sartore-Bianchi; Alessio Amatu; Erica Bonazzina; Stefano Stabile; Laura Giannetta; Giulio Cerea; Ilaria Schiavetto; Katia Bencardino; Chiara Funaioli; Riccardo Ricotta; Tiziana Cipani; Michele Schirru; Valentina Gambi; Laura Palmeri; Giulia Carlo-Stella; Francesca Rusconi; Sara Di Bella; Giovanni Burrafato; Andrea Cassingena; Emanuele Valtorta; Calogero Lauricella; Federica Pazzi; Alessandra Gambaro; Silvia Ghezzi; Giovanna Marrapese; Emiliana Tarenzi; Silvio Veronese; Mauro Truini; Angelo Vanzulli; Salvatore Siena
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

9.  Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Authors:  Sarah Watson; Jessica Menis; Capucine Baldini; Patricia Martin-Romano; Jean-Marie Michot; Antoine Hollebecque; Jean-Pierre Armand; Christophe Massard; Jean-Charles Soria; Sophie Postel-Vinay; Xavier Paoletti
Journal:  Br J Cancer       Date:  2018-10-17       Impact factor: 7.640

10.  Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.

Authors:  Andrew Dean; Aisling Byrne; Mira Marinova; Ingrid Hayden
Journal:  Biomed Res Int       Date:  2016-07-21       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.